Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine

  • Castellsagué, Joan|||0000-0002-2579-3137
  • Gel, Bernat|||0000-0001-8878-349X
  • Fernández-Rodríguez, Juana
  • Llatjós, Roger
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Pérez-Sidelnikova, Diana
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Viñals, Joan Maria
  • Vidal, August|||0000-0001-5727-2099
  • Valdés-Mas, Rafael
  • Terribas, Ernest
  • López-Doriga, Adriana
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Capella, Gabriel|||0000-0002-4669-7320
  • Puente, Xose S.|||0000-0001-9525-1483
  • Serra, Eduard|||0000-0003-2895-9857
  • Villanueva Garatachea, Alberto
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. We present the generation and characterization of five distinct MPNST orthoxenograft models for preclinical testing and personalized medicine. Four of the models are patient-derived tumor xenografts (PDTX), two independent MPNSTs from the same NF1 patient and two from different sporadic patients. The fifth model is an orthoxenograft derived from an NF1-related MPNST cell line. All MPNST orthoxenografts were generated by tumor implantation, or cell line injection, next to the sciatic nerve of nude mice, and were perpetuated by 7-10 mouse-to-mouse passages. The models reliably recapitulate the histopathological properties of their parental primary tumors. They also mimic distal dissemination properties in mice. Human stroma was rapidly lost after MPNST engraftment and replaced by murine stroma, which facilitated genomic tumor characterization. Compatible with an origin in a catastrophic event and subsequent genome stabilization, MPNST contained highly altered genomes that remained remarkably stable in orthoxenograft establishment and along passages. Mutational frequency and type of somatic point mutations were highly variable among the different MPNSTs modeled, but very consistent when comparing primary tumors with matched orthoxenografts generated. Unsupervised cluster analysis and principal component analysis (PCA) using an MPNST expression signature of ~1,000 genes grouped together all primary tumor-orthoxenograft pairs. Our work points to differences in the engraftment process of primary tumors compared with the engraftment of established cell lines. Following standardization and extensive characterization and validation, the orthoxenograft models were used for initial preclinical drug testing. Sorafenib (a BRAF inhibitor), in combination with doxorubicin or rapamycin, was found to be the most effective treatment for reducing MPNST growth. The development of genomically well-characterized preclinical models for MPNST allowed the evaluation of novel therapeutic strategies for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer

  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Tonda, Raúl
  • Gausachs, Mireia
  • Trotta, Jean-Rémi
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • López-Doriga, Adriana
  • Teule, Alex|||0000-0003-0028-7200
  • Tornero, Eva
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Gel, Bernat|||0000-0001-8878-349X
  • Gut, Marta|||0000-0002-4063-7159
  • Pineda, Marta|||0000-0002-5403-5845
  • González, Sara
  • Menéndez, Mireia
  • Navarro, Matilde
  • Capella, Gabriel|||0000-0002-4669-7320
  • Gut, Ivo|||0000-0001-7219-632X
  • Serra, Eduard|||0000-0003-2895-9857
  • Brunet, Joan|||0000-0003-1945-3512
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Lázaro García, Conxi|||0000-0002-7198-5906
Next generation sequencing panels have been developed for hereditary cancer, although there is some debate about their cost-effectiveness compared to exome sequencing. The performance of two panels is compared to exome sequencing. Twenty-four patients were selected: ten with identified mutations (control set) and fourteen suspicious of hereditary cancer but with no mutation (discovery set). TruSight Cancer (94 genes) and a custom panel (122 genes) were assessed alongside exome sequencing. Eightythree genes were targeted by the two panels and exome sequencing. More than 99% of bases had a read depth of over 30x in the panels, whereas exome sequencing covered 94%. Variant calling with standard settings identified the 10 mutations in the control set, with the exception of MSH6 c.255dupC using TruSight Cancer. In the discovery set, 240 unique non-silent coding and canonic splice-site variants were identified in the panel genes, 7 of them putatively pathogenic (in ATM, BARD1, CHEK2, ERCC3, FANCL, FANCM, MSH2). The three approaches identified a similar number of variants in the shared genes. Exomes were more expensive than panels but provided additional data. In terms of cost and depth, panels are a suitable option for genetic diagnostics, although exomes also identify variants in non-targeted genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive constitutional genetic and epigenetic characterization of lynch-like individuals

  • Dámaso, Estela|||0000-0002-9650-7791
  • González-Acosta, Maribel|||0000-0002-2468-3876
  • Vargas-Parra, Gardenia|||0000-0003-1378-736X
  • Navarro, Matilde
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Tuset, Noemí
  • Thompson, Bryony A.
  • Marín, Fátima
  • Fernández, Anna
  • Gómez, Carolina
  • Velasco, Àngela
  • Solanes, Ares
  • Iglesias Casals, Sílvia
  • Urgel, Gisela
  • López, Consol
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Campos, Olga
  • Santacana, Maria|||0000-0003-1975-2598
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Valle, Laura|||0000-0003-0371-0844
  • Brunet, Joan|||0000-0003-1945-3512
  • Pineda, Marta|||0000-0002-5403-5845
  • Capella, Gabriel|||0000-0002-4669-7320
The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five-present in 6 unrelated individuals-were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutional MLH1 epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS.